22 November 2022
Researchers in St. Petersburg have come up with what they say is an “effectual” drug candidate to treat Alzheimer’s related degenerative cerebral dysfunctions. The St. Petersburg Institute of Bioregulation and Gerontology and the Pavlov Institute of Physiology are behind the research effort.
As they experimented with Alzheimer’s mouse models, the scientists found out that using special peptides could help prevent and even reverse in the test mice’s brains the loss of what physiologists refer to as dendritic spines – special postsynaptic structures that are responsible for memory mechanisms and particularly involved in forming new memories – thus having cerebral functions fully restored.
The peptide candidate is considered “unique” and safe as no side effects have been reported.
Merry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
Long-term potential revealed for novel modifier gene therapy
21 January 2025
Binnopharm Group opened an office in Vietnam
21 January 2025
New guidance to aid cost-effectiveness analysis of new drugs
20 January 2025
The Ministry of Health may expand its patent use powers
20 January 2025